The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...
That was one of the pieces of feedback from my recent article about short- and intermediate-term portfolios, which mainly leaned on Fidelity funds for their fixed-income holdings. But Vanguard also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback